Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Prognostic role of SCAMP family in acute myeloid leukemia

The Pharmacogenomics Journal volume 20, pages 595–600 (2020)Cite this article

Subjects

Abstract

Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem or progenitor cells characterized by abnormal proliferation of primary and immature myeloid cells in bone marrow and peripheral blood. Gene mutation and expression profiles can be used as prognosis predictors for different prognostic subgroups. Secretory carrier-associated membrane proteins (SCAMPs) are a multigenic family with five members and act as cell surface vectors in the post-Golgi recycling pathways in mammals. Nevertheless, the prognostic and clinical influence of SCAMP family has hardly ever been illustrated in AML. In our study, expression patterns of SCAMP family (SCAMP1–5) were analyzed in 155 AML patients which were extracted from the Cancer Genome Atlas database. In chemotherapy, only subgroup, higher SCAMP1 level was significantly associated with longer EFS and OS (all P = 0.002), and SCAMP1 was confirmed to be an independent favorable factor in un-transplanted patients by Multivariate analysis (all P < 0.05). Nevertheless, in the allogeneic hematopoietic stem cell transplantation (allo-HSCT) treatment subgroup, none of the SCAMP genes had any effect on the clinical survival. Our study found that high expression level of SCAMP1 is a favorable prognostic factor in AML, but allo-HSCT may neutralize its prognostic effect.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Kaplan–Meier curves of event-free survival (EFS) and overall survival (OS) in patients who received chemotherapy-only.

Similar content being viewed by others

References

  1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.

    Article  CAS  Google Scholar 

  2. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Bhatt VR et al. NCCN Clinical Practice Guidelines in Oncology Acute Myeloid Leukemia (version 3.2018). NCCN Guidel. 2018. https://doi.org/10.1056/NEJMra1406184.

  3. Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, et al. Prognostic impact of low allelic ratio FLT3- ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2:2744–54.

    Article  CAS  Google Scholar 

  4. Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013;121:2734–8.

    Article  CAS  Google Scholar 

  5. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, van Putten WL, Valk PJM, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009;113:3088–92.

    Article  CAS  Google Scholar 

  6. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer and unfavorable prognosis. Blood 2011;117:2348–57.

    Article  CAS  Google Scholar 

  7. Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CAJ, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 2012;97:388–92.

    Article  CAS  Google Scholar 

  8. Zong X, Yao H, Wen L, Ma L, Wang Q, Yang Z, et al. ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis. Leuk Lymphoma 2017;58:204–6.

    Article  Google Scholar 

  9. Fathi AT, Chen Y. Bin. Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res. 2011;1:175–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Bowen D, Groves M, Burnett A, Patel Y, Allen C, Green C, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 2009;23:203–6.

    Article  CAS  Google Scholar 

  11. Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, et al. DNMT3A mutations in acute myeloid leukemia-stability during disease evolution and the clinical implication. Blood 2011;118:559–69.

    Article  Google Scholar 

  12. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.

    Article  Google Scholar 

  13. Cui L, Cheng Z, Liu Y, Dai Y, Pang Y, Jiao Y et al. Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia. Cancer Gene Ther. 2018. https://doi.org/10.1038/s41417-018-0071-9.

  14. Cheng Z, Dai Y, Pang Y, Jiao Y, Zhao H, Zhang Z, et al. Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia. Cancer Gene Ther. 2019;26:17–25.

    Article  CAS  Google Scholar 

  15. Zhang L, Li R, Hu K, Dai Y, Pang Y, Jiao Y et al. Prognostic role of DOK family adapters in acute myeloid leukemia. Cancer Gene Ther. 2018. https://doi.org/10.1038/s41417-018-0052-z.

  16. Han C, Chen T, Yang M, Li N, Liu H, Cao X. Human SCAMP5, a novel secretory carrier membrane protein, facilitates calcium-triggered cytokine secretion by interaction with SNARE machinery. J Immunol 2009;182:2986–96.

    Article  CAS  Google Scholar 

  17. Brand SH, Laurie SM, Mixon MB, Castle JD. Secretory carrier membrane proteins 31-35 define a common protein composition among secretory carrier membranes. J Biol Chem. 1991;266:18949–57.

    CAS  PubMed  Google Scholar 

  18. Brand SH, Castle JD. SCAMP 37, a new marker within the general cell surface recycling system. EMBO J 1993;12:3753–61.

    Article  CAS  Google Scholar 

  19. Wu TT, Castle JD. Evidence for colocalization and interaction between 37 and 39 kDa isoforms of secretory carrier membrane proteins (SCAMPs). J Cell Sci. 1997;110:1533–41.

    CAS  PubMed  Google Scholar 

  20. Singleton DR, Wu TT, Castle JD. Three mammalian SCAMPs (secretory carrier membrane proteins) are highly related products of distinct genes having similar subcellular distributions. J Cell Sci. 1997;110:2099–107.

    CAS  PubMed  Google Scholar 

  21. Krebs CJ, Pfaff DW. Expression of the SCAMP-4 gene, a new member of the secretory carrier membrane protein family, is repressed by progesterone in brain regions associated with female sexual behavior. Mol Brain Res. 2001;88:144–54.

    Article  CAS  Google Scholar 

  22. Choi YP, Shim HS, Gao MQ, Kang S, Cho NH. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett 2011;307:62–71.

    Article  CAS  Google Scholar 

  23. Yang S, Lee KT, Lee JY, Lee JK, Lee KH, Rhee JC. Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells. Tumor Biol 2013;34:2731–9.

    Article  CAS  Google Scholar 

  24. Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, et al. MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer. Cell Death Dis. 2018;9:344.

    Article  Google Scholar 

  25. Asghari M, Abazari MF, Bokharaei H, Aleagha MN, Poortahmasebi V, Askari H, et al. Key genes and regulatory networks involved in the initiation, progression and invasion of colorectal cancer. Future Sci OA 2018;4:FSO278.

    Article  CAS  Google Scholar 

  26. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010;116:1839–48.

    Article  CAS  Google Scholar 

  27. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson G, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.

    Article  Google Scholar 

  28. Biewenga P, Buist MR, Moerland PD, van Themaat EVL, van Kampen AHC, ten Kate FJW, et al. Gene expression in early stage cervical cancer. Gynecol Oncol 2008;108:520–6.

    Article  CAS  Google Scholar 

  29. Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res 2014;38:751–5.

    Article  CAS  Google Scholar 

  30. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008;22:1539–41.

    Article  CAS  Google Scholar 

  31. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. Cancer 2016;122:3484–91.

    Article  CAS  Google Scholar 

  32. Juliusson G, Antunovic P, Derolf Å, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179–87.

    Article  CAS  Google Scholar 

  33. Bacher U, Haferlach C, Alpermann T, Kern W, Schnittger S, Haferlach T. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Haematologica 2011;96:1284–92.

    Article  Google Scholar 

  34. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424–33.

    Article  CAS  Google Scholar 

  35. Held G, Zenz T, Lubbert M, Paschka P, Krauter J, Kugler C-M, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012;119:2114–21.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Xinjiang Joint Fund of National Natural Science Foundation of China (U1903117), the National Natural Science Foundation of China (81500118) to LF; the National Natural Science Foundation of China (61501519) to JS; and the National Natural Science Foundation of China (81600089) to JC.

Author information

Author notes

  1. These authors contributed equally: Tingting Qian, Zhiheng Cheng

Authors and Affiliations

  1. Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, 510260, Guangzhou, China

    Tingting Qian, Liang Quan, Wenhui Huang, Ling Liu, Ying Pang, Xu Ye & Lin Fu

  2. Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, 510260, Guangzhou, China

    Tingting Qian, Liang Quan, Wenhui Huang, Jinghong Chen, Cong Deng & Lin Fu

  3. Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

    Zhiheng Cheng & Yifeng Dai

  4. Department of Biomedical Sciences, University of Sassari, Sassari, Italy

    Tiansheng Zeng

  5. Translational Medicine Center, Huaihe Hospital of Henan University, 475000, Kaifeng, China

    Longzhen Cui, Yan Liu & Lin Fu

  6. Department of Hematology, Huaihe Hospital of Henan University, 475000, Kaifeng, China

    Longzhen Cui, Yan Liu & Lin Fu

  7. Department of Operations and Information Management, China-Japan Friendship Hospital, 100029, Beijing, China

    Chaozeng Si

  8. Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, 310058, Hangzhou, China

    Yang Jiao

  9. Department of Biomedical Engineering, Chinese PLA General Hospital, 100853, Beijing, China

    Jinlong Shi

Authors
  1. Tingting Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiheng Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tiansheng Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Longzhen Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chaozeng Si
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wenhui Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yifeng Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jinghong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ling Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yang Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Cong Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ying Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Xu Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jinlong Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Lin Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lin Fu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qian, T., Cheng, Z., Quan, L. et al. Prognostic role of SCAMP family in acute myeloid leukemia. Pharmacogenomics J 20, 595–600 (2020). https://doi.org/10.1038/s41397-020-0149-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-020-0149-2

This article is cited by

Search

Advanced search

Quick links